BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ... [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
Cash Position: $175 million Norwegian Kroner, projected to fund operations until the third quarter of 2025. Release Date: November 13, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript. BerGenBio ASA ( FRA:7BG0 ) has identified a significant unmet medical need in STK 11 mutated patients, presenting a substantial market opportunity. The company has received a fast-track designation from the FDA for its treatment, indicating potential for expedited development and review. BerGenBio ASA ( FRA:7BG0 ) has a strong safety database, having studied its molecule in over 600 patients, which supports its ongoing clinical trials. The company is leading efforts in addressing STK 11 mutated populations with its AXL inhibitor, positioning itself as a pioneer in this niche. Financially, BerGenBio ASA ( FRA:7BG0 ) is stable, with sufficient cash reserves projected to fund operations into the third quarter of 2025. The company has
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR Newswire
- ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferencePR Newswire
- ADC Therapeutics SA (NYSE: ADCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- ADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR Newswire
ADCT
Earnings
- 11/7/24 - Beat
ADCT
Sec Filings
- 2/14/25 - Form 4
- 2/14/25 - Form 4
- 2/14/25 - Form 4
- ADCT's page on the SEC website